"If you're not using an intravascular imaging modality, the PCI is not optimal," explained Haroon Faraz, MD, from Hackensack University Medical Center. Faraz is hopeful new and improved technologies will help these modalities become more popular among interventional cardiologists.

AstraZeneca has stopped selling Andexxa because randomized data suggested some patients may face an increased risk of certain adverse events. The company emphasized that it remains confident in the agent's abilities.

The Volt Pulsed Field Ablation System from Abbott has been approved by the FDA. The technology, which gained CE mark approval in March, features a one-of-a-kind catheter design and allows patients to be treated under conscious sedation.

An exclusive report from local NBC affiliate KARE 11 tells the story of Noah Leopold, a man who died after receiving two new hearts. The first deteriorated, and the second one killed him. Now, his family is suing, saying the Mayo Clinic failed to inform them of the risks. The nonprofit health system denies the allegations. 

Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo. 

PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.

One of the event's primary takeaways was that interventional cardiology does still attract a healthy number of trainees. However, SCAI sees several ways the specialty can improve to be even more appealing in the future. 

PFA has emerged as the preferred ablation strategy for many electrophysiologists, but some questions do remain about its long-term impact. HRS is developing this new registry to be as user-friendly for clinicians as possible.